Table IV
Description of the patients with MRONJ.
Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | Patient 9 | Patient 10 | |
---|---|---|---|---|---|---|---|---|---|---|
Sex | Female | Female | Male | Female | Male | Female | Female | Female | Female | Female |
Age | 55 | 62 | 82 | 86 | 44 | 70 | 62 | 72 | 61 | 61 |
Site | Sector 4 | Sectors 1 and 2 | Sector 2 | Sector 1 | Sectors 1 and 2 | Sector 3 | Sector 2 | Sector 4 | Sector 4 | Sectors 3 and 4 |
MRONJ stage | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
Primary cancer | Breast | Breast | Prostate | Breast | Nasopharyngeal | Breast | Breast | Breast | Breast | Kidney |
Concomitant treatment | Capecitabine, letrozole, exemestane, everolimus, fulvestrant, palbociclib | Capecitabine, cyclophosphamide | Corticosteroids docetaxel trihydrate, leuprolide, enzalutamide | Corticosteroids fulvestrant, palbociclib | Corticosteroids methotrexate carboplatin doxorubicin | Letrozole, palbociclib, fulvestrant | Corticosteroids exemestane/ everolimus, fulvestrant, palbociclib, capecitabine/ cyclophosphamide | Letrozole, fulvestrant, palbociclib capecitabine | Tamoxifen, letrozole | Sunitinib, cabozantinib |
Dental check-up* | Infection | Infection | Infection | Infection | / | Infection | Infection | Infection | Infection | Infection |
Periodontal disease** | + | + | + | – | +++ | + | +++ | +++ | + | + |
Removable prosthesis | / | Mx compressive Overnight wearing | Mx compressive | Bimaxillary Overnight wearing | / | / | Mx | Mx Md instability | Mx | / |
Extracted teeth | 45 + Non-surgical periodontal therapy | 16, 17, 27, 37, 36 | 22, 26, 45, 35 | 44 | Non-surgical periodontal therapy | 37 | 15, 16, 25, 35 | 42, 13 | 13, 43, 44, 47 | 13, 14, 15 |
Interval between tooth extraction and denosumab initiation | 3 weeks*** | 3 weeks*** | 3 months | 3 months | Not concerned | 3 months | 3 months | 3 months | 3 months | 3 months |
Total follow-up from denosumab initiation | 29 months | 15 months | 18 months | 34 months | 15 months | 30 months | 34 months | 23 months | 22 months | 22 months |
Number of injections at the time of MRONJ diagnosis | 10 | 12 | 8 | 24 | 12 | 19 | 20 | 12 | 15 | 11 |
MRONJ management at the end of follow up | Conservative / Surgery$ | Conservative | Conservative | Conservative | Conservative | Conservative / Surgery$ | Conservative / Surgery$ | Conservative | Conservative | Conservative / Surgery$ |
MRONJ status at the end of follow up | Remission | Unknown / death (during the temporization period€) |
Stabilization (during the temporization period€) | Stabilization (during the temporization period€) | Unknown / death (during the temporization period€) |
Improvement (during the healing period£) | Improvement (during the healing period£) | Stabilization (during the temporization period€) | Stabilization (during the temporization period€) | Worsening (after surgery) |
Follow-up after MRONJ diagnosis | 16 months (10 months after MRONJ management) |
4 months | 4 months | 5 months | 2 months | 8 months (1month after MRONJ management |
7 months, (1month after MRONJ management) |
6 months | 1 months | 10 months (1 month after surgery) |
Denosumab reintroduction | Yes, without recurrence after 4 injections | / | / | / | / | Considered | / | / | / | / |
** Periodontal disease: “-” absence of periodontal disease, “+” chronic and stable periodontitis, “+++” severe periodontal disease.and acute infection.
$ Conservative / Surgery: conservative management was put in place during the period of decreasing effectiveness of the antiresorptive drug, then the MRONJ surgical management was performed.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.